Scribd
Upload
93 views24 pages

Ranbaxy Laboratories Limited: To Become A Research Based International Pharmaceutical Company

Ranbaxy Laboratories Limited aims to become a research-based international pharmaceutical company. It has a strong presence in generics and innovative research capabilities. In 2008, Ranbaxy recorded global sales of $1.682 billion with products sold in over 40 countries and manufacturing in 6 countries. It employs around 7,000 people of 17% non-Indian origin. Ranbaxy has over 1,200 scientists engaged in research and development across multiple facilities. It maintains a focus on chronic and lifestyle disease segments through strategic acquisitions and alliances.

Uploaded by

mnjbash
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
93 views24 pages

Ranbaxy Laboratories Limited: To Become A Research Based International Pharmaceutical Company

Ranbaxy Laboratories Limited aims to become a research-based international pharmaceutical company. It has a strong presence in generics and innovative research capabilities. In 2008, Ranbaxy recorded global sales of $1.682 billion with products sold in over 40 countries and manufacturing in 6 countries. It employs around 7,000 people of 17% non-Indian origin. Ranbaxy has over 1,200 scientists engaged in research and development across multiple facilities. It maintains a focus on chronic and lifestyle disease segments through strategic acquisitions and alliances.

Uploaded by

mnjbash
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
You are on page 1/ 24

Ranbaxy Laboratories Limited

(Since 1961)

To become a Research based International Pharmaceutical Company

Presented By: Aniruddha Nayak Roll- 7 PGDM- II

Key Drivers of Pharma Growth


Value of Drugs going off patent 2006 - 11
35

Significant patent expiries through 2011

30 25 20 15 10 5 0
2006 2007 2008 2009 2010 2011

$ Bn

Source : IMS

Increasing genericisation
France Spain Italy

Accelerating branded generics


Russia South Africa India

Rationalizing Healthcare costs - key priority for Governments

Key Issues
Increasing competition

Increasing focus on costs

Consolidation - Changing Landscape

The India Pharma Story

Source Financial Times

The Indian Pharmaceutical Industry today is in the front rank of Indias science-based industries .
The Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually.

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units
Several Indian pharmaceutical companies have acquired companies in the US and Europe and many others .

Ranbaxy Today
Worldwide Presence

India's largest Ranked 8th amongst the global generic pharmaceutical companies Ground presence in 49 countries, products sold in > 125
Global Sales
$ 1339

International business ~ 80% of sales Manufacturing locations in 11 countries

$ 972

> 11,000 employees, 51 nationalities


$ 553

Strong Generics & Innovative research


2001 2003 2006

capabilities

For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn,
R&D has a pool of over 1,200 scientists engaged in research

Products sold in over 40 countries; manufacturing operations in 6 countries including India

Employs about 7000 people, 17% of non Indian origin

Expanding portfolio of international subsidiaries, joint ventures, affiliates and alliances

Ranbaxy 11%

GSK 1% Cipla 13%

Others 60% Cadilla 8%

Nicholas 7%

MISSION:To become a research based international pharmaceutical company.

VISION:Achieving customer satisfaction is fundamental to our business. Provide product and service of the highest quality. Manage our operation with high concern for strategy and environment. Be a responsible corporate citizen.

India
Fastest growing Company in India
(Source :ORG-IMS Mat Mar 2007) Ranbaxy GSK 5.0% Cipla 4.9% 5.1%

65 new products introduced in 2006


First to market NDDS In-licensed 10 6 8

Source : ORG IMS Audit Nov 2006, Moving Quarter Basis

Dedicated task forces for Specialized & Chronic therapies

21 brands in Top 300 of Industry ( 2005 :19)

Source : IMS - ORG

Research & Development


New R&D facility for Drug Discovery Research (DDR)

R&D III

R&D I

R&D II

R&D IV

Research & Development


Dedicated Facilities for Innovative & Generics Research > 1400 R&D Personnel ( ~ 250 PhDs)

8 - 10 NCE molecules in pipeline


NDDS based products ( 4 platform technologies) R&D collaborations
Alliance / Collaboration in DDR Out-licensing in NDDS

Out-licensing
in DDR

Ranbaxy GSK Collaboration


Expansion of strategic alliance established in 2003 Take leads beyond candidate selection to POC* in man Therapeutic area focus of AI, Metabolic, Anti-inflammatory and Oncology

> US$ 100 mn in milestone payments and double digit


royalties on commercialization of a product Co- marketing rights in India First candidate identified for Respiratory Inflammation
Proof of Concept

Major Acquisitions & Alliances

Terapia (Romania)

Zenotech (India)
Krebs (India) Jupiter Biosciences*(Ind.) Cardinal Drugs (India) Auto-injector Tech.(USA)

Be-Tabs (South Africa)


Allen (Italy) Ethimed (Belgium) Mundogen (Spain)

* Subject to due diligence

Niche Alliances
Increasing focus on chronic / lifestyle diseases segment High entry barriers - technology & resource intensive

Zenotech Bio-similars & Oncologics

Jupiter* Peptides

Krebs Fermentation based products

* Subject to due diligence

BRAND RANBAXY
OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALITY

OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALITY

0% 0%

28%

Good

Best

Poor

72%

Bad

Ranbaxy Brands

Analgesics

Anti-Peptic Ulcerants

Cardiovasculars
CNS Cough Preparations & Anti-Histamines Diagnostic Instruments Oral Anti-Diabetics Other Anti-Infectives

Cephalosporins
Combination Therapy Dermatologicals Nutritionals Orthopaedic Segment Others

Quinolones
Reagents-Cardiac Markers Reagents-Serology Semi-Synthetic Penicillins

Reagents-Biochemistry
Reagents-HIV/Hepatitis Reagents-Torch Range

KEY PARAMETERS OF PROMOTIONAL STRATEGY OF RANBAXY

Regular promotion through MR

10%

Complements and Gifts

8%

Continued Medical Education


6% 50%

Seminars
8%

Educational Tour
18%

CRM

Repositioning Ranbaxy
underwent a sea change during the period 1985-1995
diversified into different products, markets and in general over the value curve tried to create differentiation through Marketing and Process Technology, resulted in improved product/brand profitability, and an increase in brand life cycle

Revitalising the brand


one of the top brands from the Ranbaxy stable that made a successful transition from prescription to OTC markets in India. Ranbaxy's Revital successfully shifted from prescription to OTC and became a market leader. Jiyo Jee Bhar Ke Yuvraj bats for Ranbaxys healthcare brand

In Summary
A strong performance on all parameters Buoyant performance across key geographies Continuing focus on cost optimization Robust product flow Growth through organic & inorganic Discovery pipeline progressing well Global Generic rank 8th

Thank You

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy